IQVIA (NYSE:IQV) Cut to Hold at Hsbc Global Res

IQVIA (NYSE:IQV - Get Free Report) was downgraded by equities research analysts at Hsbc Global Res from a "strong-buy" rating to a "hold" rating in a research note issued to investors on Friday,Zacks.com reports.

Other equities analysts have also recently issued research reports about the company. StockNews.com cut IQVIA from a "buy" rating to a "hold" rating in a report on Wednesday, March 12th. Robert W. Baird lowered their price target on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 21st. Truist Financial lowered their target price on IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a report on Thursday, April 10th. HSBC lowered shares of IQVIA from a "buy" rating to a "hold" rating and reduced their price target for the company from $260.00 to $160.00 in a research report on Friday, April 25th. Finally, Citigroup reduced their price target on shares of IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Eight research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, IQVIA has a consensus rating of "Moderate Buy" and an average price target of $237.62.

IQVIA Price Performance

NYSE IQV traded down $2.13 during trading hours on Friday, reaching $152.94. The company's stock had a trading volume of 704,676 shares, compared to its average volume of 1,429,209. The company has a market capitalization of $26.96 billion, a price-to-earnings ratio of 20.36, a PEG ratio of 1.99 and a beta of 1.46. IQVIA has a 1 year low of $135.97 and a 1 year high of $252.88. The firm's 50-day moving average price is $169.14 and its 200-day moving average price is $192.46. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, equities research analysts predict that IQVIA will post 10.84 EPS for the current fiscal year.

Institutional Trading of IQVIA

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Norges Bank acquired a new position in shares of IQVIA in the 4th quarter worth approximately $336,041,000. Raymond James Financial Inc. bought a new position in IQVIA in the 4th quarter valued at $236,120,000. American Century Companies Inc. raised its position in IQVIA by 396.0% in the 4th quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company's stock valued at $222,987,000 after purchasing an additional 905,960 shares during the last quarter. Invesco Ltd. raised its position in IQVIA by 53.4% in the 4th quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock valued at $509,012,000 after purchasing an additional 902,226 shares during the last quarter. Finally, Canada Pension Plan Investment Board raised its position in IQVIA by 20.0% in the 4th quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock valued at $841,461,000 after purchasing an additional 712,958 shares during the last quarter. Institutional investors own 89.62% of the company's stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.